Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs ZLAB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IONS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

IONS Overall Winner 6-Pillar Tally: IONS 3 – 3 ZLAB Matrix Metrics: IONS 6 – 4 ZLAB

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin).

  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs ZLAB
IONS NASDAQ Head-to-Head Winner
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57

6-Pillar Scorecard Institutional Category Breakdown (IONS 3 – 3 ZLAB)

Columns: Metric · IONS · ZLAB
1. Valuation Multiples IONS
Forward P/E 90.9x N/M
Trailing P/E 90.9x N/M
PEG Ratio N/M N/M
EV / Revenue 6.2x 6.8x
2. Growth & Scale IONS
Revenue Growth (YoY) +54.9% -6.8%
Earnings Growth (YoY) -43.7% +0.0%
TTM Revenue (USD) $960M $442M
Market Cap $4.7B $3.0B
3. Profitability & Quality IONS
Gross Margin 3.0% 0.6%
Operating Margin -58.8% -63.0%
Net Profit Margin -56.9% -44.9%
Return on Equity (ROE) -108.0% -30.0%
4. Balance Sheet & Cash Flow ZLAB
Cash Generation (TTM) -$623M -$262M EBITDA
Cash Flow Margin -64.9% -59.3% EBITDA Mgn
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $5.01 Book/Sh · -30.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZLAB
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 59.9% (17th %ile) 58.4% (58th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 61.8% of Rev ($593M) 63.6% of Rev ($281M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (6) vs ZLAB (4)
Institutional Metric IONS ZLAB Criterion Row Edge
Market Capitalization
Scale
$4.7B $3.0B Larger Scale IONS
Trailing P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Forward P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Revenue Growth (YoY)
Growth
+54.9% -6.8% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% -63.0% Higher Margin IONS
Net Profit Margin
Profitability
-56.9% -44.9% Higher Margin ZLAB
Return on Equity (ROE)
Capital Efficiency
-108.0% -30.0% Higher ROE ZLAB
52-Week Range Position
Momentum
2% ($27–$87) 60% ($16–$29) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.19β · 78% Vol Lower Realized Risk ZLAB
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 47.4 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $442M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 0.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 6.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZLAB +35.85 pp
IONS: -33.48% · ZLAB: +2.37%
3M Horizon ZLAB +44.93 pp
IONS: -52.09% · ZLAB: -7.16%
6M Horizon ZLAB +86.48 pp
IONS: -60.61% · ZLAB: +25.87%
1Y Horizon ZLAB +68.35 pp
IONS: -59.1% · ZLAB: +9.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IONS vs ZLAB. Trailing 12-month operating profitability (IONS -58.8% vs ZLAB -63.0%) and valuation multiples (IONS 90.9x vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IONS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$960M
Gross Margin3.0%
Op. Margin-58.8%
ROE / Fwd P/E-108.0% · 90.9x
ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs ZLAB Key Questions & Quantitative Answers

As of Nov 16, 2026, Ionis Pharmaceuticals, Inc. (IONS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IONS leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with ZLAB at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin). On trailing 12-month operating scale, IONS generates $960M in USD-normalized revenue versus $442M for ZLAB. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 63.6% of Rev ($281M) (0 disclosures) for ZLAB.

IONS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus ZLAB (-30.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.